Stock analysts at JMP Securities started coverage on shares of TELA Bio (NASDAQ:TELA) in a research report issued to clients and investors on Tuesday, The Fly reports. The firm set an “outperform” rating on the stock.
Several other equities analysts have also issued reports on TELA. Piper Jaffray Companies began coverage on TELA Bio in a report on Tuesday. They set an “overweight” rating on the stock. Canaccord Genuity initiated coverage on TELA Bio in a report on Tuesday. They issued a “buy” rating for the company.
Shares of TELA opened at $12.31 on Tuesday. TELA Bio has a 1-year low of $10.78 and a 1-year high of $15.05.
TELA Bio Company Profile
TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Further Reading: Why is a lock-up period needed for an IPO?
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.